UCB SA (OTCMKTS:UCBJF – Get Free Report) shares saw an uptick in trading volume on Tuesday . Approximately 9,277 shares were traded during trading, an increase of 1,063% from the previous session’s volume of 798 shares.The stock last traded at $263.3625 and had previously closed at $263.84.
Analysts Set New Price Targets
Several brokerages recently commented on UCBJF. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research report on Monday. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.
Get Our Latest Stock Analysis on UCB
UCB Stock Down 2.0%
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Recommended Stories
- Five stocks we like better than UCB
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
